Prevalence of metabolic syndrome in patients with pulmonary hypertension

Kamonpun Ussavarungsi, Colleen S. Thomas, Charles Dwayne Burger

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background and Aims: To determine the prevalence of metabolic syndrome (MetS) - a potential phenotypical risk for pulmonary hypertension (PH) - in patients with PH and by PH diagnostic group including group 1 pulmonary arterial hypertension (PAH); group 1.1 idiopathic PAH, groups 1.2 heritable PAH, 1.3 drug and toxin induced, 1.4 associated PAH, group 2 PH with left heart disease, group 3 PH associated with lung disease and/or hypoxemia, group 4 PH owing to chronic thrombotic and/or embolic disease, and group 5 PH from multifactorial mechanisms. Methods: We conducted a retrospective chart review of patients referred to Mayo Clinic in Florida from January 1990 to October 2013 (N=1287). Only patients whom PH was confirmed by right heart catheterization were included (N=640). MetS was defined with at least three of the following: systemic hypertension, diabetes mellitus, hyperlipidemia and body mass index>30. Results: MetS was prevalent in 247 of 640 (39%) with PH: 13% in group 1.1 PAH, 12% in groups 1.2-1.4 PAH, 54% in group 2, 55% in group 3, 23% in group 4 and 24% in group 5. After adjusting for age, sex and race, diagnostic subgroup analysis revealed a higher prevalence of MetS in WHO Group 2 PH patients [adjusted odd ratios (OR): 2.58, P

Original languageEnglish (US)
JournalClinical Respiratory Journal
DOIs
StateAccepted/In press - 2015

Fingerprint

Pulmonary Hypertension
Cardiac Catheterization
Hyperlipidemias
Lung Diseases
Heart Diseases
Diabetes Mellitus
Body Mass Index
Odds Ratio

Keywords

  • Metabolic syndrome - obesity - prevalence - pulmonary hypertension - pulmonary venous hypertension

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Immunology and Allergy
  • Genetics(clinical)

Cite this

Prevalence of metabolic syndrome in patients with pulmonary hypertension. / Ussavarungsi, Kamonpun; Thomas, Colleen S.; Burger, Charles Dwayne.

In: Clinical Respiratory Journal, 2015.

Research output: Contribution to journalArticle

@article{c2e30ada5b1b4ba5bf7638651d2524cd,
title = "Prevalence of metabolic syndrome in patients with pulmonary hypertension",
abstract = "Background and Aims: To determine the prevalence of metabolic syndrome (MetS) - a potential phenotypical risk for pulmonary hypertension (PH) - in patients with PH and by PH diagnostic group including group 1 pulmonary arterial hypertension (PAH); group 1.1 idiopathic PAH, groups 1.2 heritable PAH, 1.3 drug and toxin induced, 1.4 associated PAH, group 2 PH with left heart disease, group 3 PH associated with lung disease and/or hypoxemia, group 4 PH owing to chronic thrombotic and/or embolic disease, and group 5 PH from multifactorial mechanisms. Methods: We conducted a retrospective chart review of patients referred to Mayo Clinic in Florida from January 1990 to October 2013 (N=1287). Only patients whom PH was confirmed by right heart catheterization were included (N=640). MetS was defined with at least three of the following: systemic hypertension, diabetes mellitus, hyperlipidemia and body mass index>30. Results: MetS was prevalent in 247 of 640 (39{\%}) with PH: 13{\%} in group 1.1 PAH, 12{\%} in groups 1.2-1.4 PAH, 54{\%} in group 2, 55{\%} in group 3, 23{\%} in group 4 and 24{\%} in group 5. After adjusting for age, sex and race, diagnostic subgroup analysis revealed a higher prevalence of MetS in WHO Group 2 PH patients [adjusted odd ratios (OR): 2.58, P",
keywords = "Metabolic syndrome - obesity - prevalence - pulmonary hypertension - pulmonary venous hypertension",
author = "Kamonpun Ussavarungsi and Thomas, {Colleen S.} and Burger, {Charles Dwayne}",
year = "2015",
doi = "10.1111/crj.12406",
language = "English (US)",
journal = "Clinical Respiratory Journal",
issn = "1752-6981",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Prevalence of metabolic syndrome in patients with pulmonary hypertension

AU - Ussavarungsi, Kamonpun

AU - Thomas, Colleen S.

AU - Burger, Charles Dwayne

PY - 2015

Y1 - 2015

N2 - Background and Aims: To determine the prevalence of metabolic syndrome (MetS) - a potential phenotypical risk for pulmonary hypertension (PH) - in patients with PH and by PH diagnostic group including group 1 pulmonary arterial hypertension (PAH); group 1.1 idiopathic PAH, groups 1.2 heritable PAH, 1.3 drug and toxin induced, 1.4 associated PAH, group 2 PH with left heart disease, group 3 PH associated with lung disease and/or hypoxemia, group 4 PH owing to chronic thrombotic and/or embolic disease, and group 5 PH from multifactorial mechanisms. Methods: We conducted a retrospective chart review of patients referred to Mayo Clinic in Florida from January 1990 to October 2013 (N=1287). Only patients whom PH was confirmed by right heart catheterization were included (N=640). MetS was defined with at least three of the following: systemic hypertension, diabetes mellitus, hyperlipidemia and body mass index>30. Results: MetS was prevalent in 247 of 640 (39%) with PH: 13% in group 1.1 PAH, 12% in groups 1.2-1.4 PAH, 54% in group 2, 55% in group 3, 23% in group 4 and 24% in group 5. After adjusting for age, sex and race, diagnostic subgroup analysis revealed a higher prevalence of MetS in WHO Group 2 PH patients [adjusted odd ratios (OR): 2.58, P

AB - Background and Aims: To determine the prevalence of metabolic syndrome (MetS) - a potential phenotypical risk for pulmonary hypertension (PH) - in patients with PH and by PH diagnostic group including group 1 pulmonary arterial hypertension (PAH); group 1.1 idiopathic PAH, groups 1.2 heritable PAH, 1.3 drug and toxin induced, 1.4 associated PAH, group 2 PH with left heart disease, group 3 PH associated with lung disease and/or hypoxemia, group 4 PH owing to chronic thrombotic and/or embolic disease, and group 5 PH from multifactorial mechanisms. Methods: We conducted a retrospective chart review of patients referred to Mayo Clinic in Florida from January 1990 to October 2013 (N=1287). Only patients whom PH was confirmed by right heart catheterization were included (N=640). MetS was defined with at least three of the following: systemic hypertension, diabetes mellitus, hyperlipidemia and body mass index>30. Results: MetS was prevalent in 247 of 640 (39%) with PH: 13% in group 1.1 PAH, 12% in groups 1.2-1.4 PAH, 54% in group 2, 55% in group 3, 23% in group 4 and 24% in group 5. After adjusting for age, sex and race, diagnostic subgroup analysis revealed a higher prevalence of MetS in WHO Group 2 PH patients [adjusted odd ratios (OR): 2.58, P

KW - Metabolic syndrome - obesity - prevalence - pulmonary hypertension - pulmonary venous hypertension

UR - http://www.scopus.com/inward/record.url?scp=84949008147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949008147&partnerID=8YFLogxK

U2 - 10.1111/crj.12406

DO - 10.1111/crj.12406

M3 - Article

C2 - 26493968

AN - SCOPUS:84949008147

JO - Clinical Respiratory Journal

JF - Clinical Respiratory Journal

SN - 1752-6981

ER -